Major in Medical Technology

Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R)

ROCKVILLE, Md., May 26 /PRNewswire/ -- Theranostics Health, Inc. (TH) is pleased to announce its involvement in a five-year clinical research study funded by the Susan G. Komen Foundation. TH's collaborator, Duke University , was the recipient of a Promise Grant, part of over $25 million of inve...

New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers

SYDNEY, April 20 /PRNewswire/ -- Australian medical research company Immune System Therapeutics Ltd (IST) has launched a clinical trial to test its breakthrough treatment for terminal blood cancers. IST has genetically engineered an antibody drug that binds specifically to a target protein fo...

Isogen Launches Major New Facility to Address Global Biopharma Demand

NEWARK, Del., Nov. 19 /PRNewswire/ -- Isogen, a contract development and manufacturing organization for sterile filling, today announced the first phase launch of its contract facility in Delaware. Isogen was founded to specifically address the process, facility and capacity problems commonly asso...

MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy

Study Results Published in the September 18th New England Journal of Medicine Each year more than 52,000 Americans die from colorectal cancer. Many of these deaths could be prevented by regular screening. Yet, the vast majority of those 50 and older who should be screened for the disease are...

Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community

Study findings offer hope for increased life expectancy for people with Down syndrome WASHINGTON, Aug. 18 /PRNewswire-USNewswire/ -- In the world of Down syndrome, 'Mr. C' is a rarity. A real person whose progress has been tracked for the past 16 years, at seventy, 'Mr. C' has well surpassed...

First Ever Study on Alzheimer's Disease Treatment in Hispanics Presented at Major Medical Meeting

ARICEPT(R) (donepezil HCl tablets) Now the Only Alzheimer's Disease Drug Studied in Two Minority Groups CHICAGO, July 30, 2008 /PRNewswire/ -- Eisai Inc. and Pfizer Inc (NYSE: PFE) announced today results from a new open-label study that showed Hispanics with mild to modera...

Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder

Owing to Safety, Escitalopram Will Remain as the Clinical Gold Standard Treatment, According to a New Report from Decision Resources WALTHAM, Mass., July 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare...

Video: Sanford Health's Journey to Cure Type 1 Diabetes Receives Major Boost

Historic $10 Million Gift Creates Fund for Sanford Project Chair SIOUX FALLS, S.D., July 10 /PRNewswire/ -- Sanford Health announced today it has received a $10 million gift from Todd and Linda Broin of Sioux Falls, SD to fund the chair of the Sanford Project. The gift for the Todd and Lin...

Oridion Announces Major Medical Research and Congress Presentations

JERUSALEM and NEEDHAM, Massachusetts, June 17 /PRNewswire-FirstCall/ -- Oridion Systems Ltd. - (SWX: ORIDN) Significant findings from numerous medical research projects demonstrating the clinical benefit of end-tidal CO2 (EtCO2) monitoring using Microstream(R) capnography technology, were rece...

Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder

Ambien CR(R) 12.5 mg significantly improved sleep onset, sleep maintenance and total sleep time compared to placebo BRIDGEWATER, N.J., June 10 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today results from a new study that showed Ambien CR(R) (zolpidem tartrate extended-re...

Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer

- Zometa when added to hormone therapy, following surgery, significantly reduced the risk of cancer returning or death by 36% beyond clinical benefits achieved with hormone therapy alone(1) - Findings may allow clinicians to improve standard of care for premenopausal women diagn...

BioElectronics Announces Major Clinical Trials

Breast augmentation and cesarean section trials in conjunction with David G. Genecov, MD, FACS, FAAP to begin immediately FREDERICK, Md., May 28 /PRNewswire-FirstCall/ -- BioElectronics Corp. (Pink Sheets: BIEL), the maker of the ActiPatch(TM), a drug free anti- inflammatory patch, w...

XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years

Patients Treated with XIENCE V in SPIRIT III Trial Experience Better Long-Term Clinical Outcomes, Lower Rates of Stent Thrombosis than Patients Treated with TAXUS BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Long-term data presented for the first time today f...

New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting

- Studies Evaluated Improvement in Symptoms Both in the Short and Long Term - WILMINGTON, Del., May 5 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced new study data on SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets for the treat...

CureDM's Diabetes Therapy Achieves Major Development Milestone

WYNNEWOOD, Pa., April 30 /PRNewswire/ -- CureDM, Inc., a biopharmaceutical company developing new therapies that prevent, ameliorate, or reverse both type 1 and 2 diabetes, announces its achievement of a major drug development milestone for Human proIslet Peptide (HIP). CureDM has successfully...

SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa

NORCROSS, Ga., April 17 /PRNewswire/ -- The SurgiLance safety lancet, an industry-leading medical safety product manufactured by MediPurpose, has been selected for inclusion in an HIV kit distributed throughout Africa by Nigerian-based Bundi International Diagnostics. Long established in the A...

Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing

- Second research program centered on potential target in inflammatory indications such as rheumatoid arthritis - NUTLEY, N.J., April 15 /PRNewswire/ -- Roche announced today that it will acquire Piramed Limited, a privately-owned UK company focusing on therapeutics targeting PI...

Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies

OMAHA, Neb., March 5 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO), a leading global genetic analysis company, today announced that it has entered into agreements with two major Pharmaceutical companies for three Phase II trials representing more than $500,000 in the ...

Cancer Cure Coalition Proposes Major Changes at the FDA

PALMS BEACH GARDENS, Fla., Feb. 21 /PRNewswire/ -- Flawed policies and bad decisions at the FDA have contributed to an escalation of the cost of clinical trials which now take an average of one billion dollars and require 10 years for approval. This has delayed and even prevented the availabil...

FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder

INDIANAPOLIS, Nov. 30 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the maintenance treatment of major depressive disorder (MDD) in adults. "Relapse, the re-emergenc...

Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression

NEW YORK, Nov. 29 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) and H. Lundbeck A/S today announced preliminary top-line results from a phase III study of LEXAPRO (escitalopram oxalate) in the treatment of adolescents, aged 12-17, with Major Depressive Disorder (MDD). These...

Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression

Non-drug, non-invasive treatment helps patients who have tried other options without success PHILADELPHIA, Nov. 26 /PRNewswire-USNewswire/ -- Researchers at the University of Pennsylvania School of Medicine and other study sites have found that transcranial magnetic stimulation (TMS) --...

Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo

"On both ethical and practical grounds, direct programming is superior to cloning as a means of obtaining patient-specific pluripotent stem cells." WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Two major scientific papers published this week in Science and Cell unveil a proven way to gener...

Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder

HOUSTON, LONDON and RESEARCH TRIANGLE PARK, N.C., Nov. 2 /PRNewswire/ -- Fabre-Kramer Pharmaceuticals Inc. (FKP) and GlaxoSmithKline (NYSE: GSK ) announced today that the U.S. Food and Drug Administration (FDA) has issued a not approvable letter for the new drug application for gepirone exten...

Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting

Analysis of study showed effect size of VYVANSE ranged from 1.39 to 1.73 BOSTON, Oct. 26 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced results from an analysis of VYVANSE(TM) (lisdexamfetamine dimesylate...

Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting

All Doses of VYVANSE Studied Demonstrated Significant Efficacy Within One Week of Daily Treatment BOSTON, Oct. 25 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced the results of a stud...

Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial

One-year Data Demonstrate Continued Safety, Consistently Positive Clinical Results with XIENCE V WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT III U.S. pivotal clinical trial demonstrated continued positive, statistically signifi...

EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases

WATERTOWN, Mass., Oct. 17 /PRNewswire/ -- EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced progress on several key programs for addressing Alzheimer's, Schizophrenia and Huntington's diseases. EnVivo Phar...

deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack

REYKJAVIK, Iceland, Oct. 11 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN ) today announced the launch of deCODE MI(TM), a reference laboratory test for variations in the genome (called SNPs) that the company has associated with increased risk of myocardial infarction, or heart atta...

ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx

WINDSOR, Ontario, Sept. 19 /PRNewswire/ -- ArtJen Complexus Holdings Corp. (http://www.fbcx.com ) today announced that, following the results of their clinical trial with obese type 2 diabetics and an animal study at the National Institutes of Health, FBCx is being studied by a major US west-...

The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor

Study results outline dabigatran etexilate as potential thromboprophylaxis therapy for patients undergoing total hip replacement surgery RIDGEFIELD, Conn., Sept. 13 /PRNewswire/ -- Boehringer Ingelheim today announced that the September 15 issue of The Lancet will publish results from the R...

Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium

SAN FRANCISCO, Sept. 7 /PRNewswire/ -- Roche announced today that three clinical data abstracts about its oral chemotherapy treatment Xeloda(R) have been accepted for presentation at the 2007 Breast Cancer Symposium in San Francisco, Sept. 7 and 8. Two of the abstracts include data from the X...

Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium

SAN FRANCISCO, Sept. 7 /PRNewswire/ -- Roche announced today that three clinical data abstracts about its oral chemotherapy treatment Xeloda have been accepted for presentation at the 2007 Breast Cancer Symposium in San Francisco, Sept. 7 and 8. Two of the abstracts include data from the XeNA...

Medivation Announces Presentation of Full Top-Line Data From Dimebon Six-Month Trial at Major International Alzheimer's Disease Conference

SAN FRANCISCO, March 19, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that six-month results from its randomized, double-blinded, placebo-controlled Phase 2 efficacy trial of Dimebon(TM) in patients with mild-to-moderate Alzheimer's disease demonstrated that patients treated wit...

REACH Registry Demonstrates That Multiple Arterial Disease Locations Sharply Increase the Risk of Major CV Events in Outpatients With Atherothrombosis

- The Reduction of Atherothrombosis for Continued Health (REACH) - Registry 1-Year Results PARIS, March 20, 2007 /PRNewswire/ --The REACH Registry 1-year results paper published today in the Journal of the American Medical Association (JAMA) show that outpatients with atherothrombosis have a s...

Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for Psychotic Major Depression Misses Primary Endpoint

STATISTICALLY SIGNIFICANT CORRELATION BETWEEN PLASMA LEVELS AND CLINICAL OUTCOME ACHIEVED DURING TREATMENT Management will host a conference call and live webcast on March 20, 2007 at 9:00 a.m. EDT MENLO PARK, Calif. (March 19, 2007) – Corcept Therapeutics Incorporated (NASDAQ: CORT), to...

New Clinical Data for Cytogen's Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings

PRINCETON, N.J.--(BUSINESS WIRE)--Mar 26, 2007 - Cytogen Corporation (NASDAQ: CYTO) today announced that five abstracts will be presented or published at upcoming major medical meetings. The data will include various Phase 1 clinical results for QUADRAMET(R) (samarium Sm-153 lexidronam injection) i...

Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C

Highlights key data at the 42nd annual meeting of the European Association for the Study of the Liver (EASL) KENILWORTH, N.J., April 11, 2007 /PRNewswire-FirstCall/ -- Schering-Plough Corporation reaffirms its commitment to advancing the science and treatment of chronic hepatitis C virus (HCV) inf...

Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference

LOS ANGELES--(BUSINESS WIRE)--Apr 16, 2007 - Introgen Therapeutics, Inc. (NASDAQ:INGN) reported updated ADVEXIN(R) biomarker data over the weekend in Los Angeles, California at the Annual Meeting of the American Association for Cancer Research. Abnormality of the p53 tumor suppressor is one of the...

CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings

BRANFORD, Conn., April 19, 2007 /PRNewswire-FirstCall/ -- CuraGen Corporation and TopoTarget A/S announced today that preliminary interim clinical data on intravenous belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, are expected to be pres...